• RG7388: Mechanistic Insights and Strategic Impact in p53 Onc

  2026-04-30

  This thought-leadership article provides translational researchers with a strategic roadmap for leveraging RG7388, a next-generation oral MDM2 antagonist, in the context of p53 pathway activation, apoptosis induction, and biomarker-driven oncology. Building on new evidence around the MDM1-p53 axis and integrating recent advances in chemoradiotherapy sensitization, the piece bridges mechanistic understanding with actionable experimental and clinical guidance. Distinct from conventional product literature, the article weaves together protocol recommendations, competitive analysis, and translational foresight for the deployment of RG7388 (SKU A3763) in precision cancer research.

• Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal S

  2026-04-30

  Moxidectin, a macrocyclic lactone anthelmintic, is redefining antifungal workflows by synergizing with polyenes against Candida albicans, as recently evidenced in advanced oral candidiasis models. This article provides actionable protocol enhancements, troubleshooting insights, and a direct translation of the latest mechanistic findings into experimental strategy for both veterinary and cross-domain research.

• Butylated Hydroxyanisole (BHA): Applied Workflows in ROS & S

  2026-04-29

  Butylated hydroxyanisole (BHA) stands out as a synthetic antioxidant for robust oxidative stress and reactive oxygen species (ROS) research. This article delivers advanced application workflows, troubleshooting strategies, and evidence-based protocol parameters, positioning APExBIO’s high-purity BHA as a benchmark tool for cellular protection and pathway modulation assays.

• G418 Sulfate (Geneticin): Selection, Antiviral Action & Mech

  2026-04-29

  G418 Sulfate (Geneticin) is a potent antibiotic used for genetic engineering selection and exhibits antiviral activity against Dengue virus serotype 2. Its specificity for cells expressing the neomycin resistance gene makes it indispensable for cell line development and molecular virology research.

• HOXC8 Regulates Pyroptosis in NSCLC via Caspase-1 Suppressio

  2026-04-28

  This study demonstrates that HOXC8, a transcription factor, suppresses caspase-1 gene expression to prevent pyroptotic cell death in non-small cell lung carcinoma (NSCLC). The findings reveal a direct mechanism by which HOXC8 influences tumorigenesis, offering new insights for inflammation research and apoptosis assays.

• Thioguanine in Cancer and Virology Research: Workflows & Inn

  2026-04-28

  Thioguanine (6-thioguanine) enables targeted inhibition of cancer cell proliferation and viral replication through dual molecular mechanisms. Recent advances in nanoparticle delivery and epigenetic modulation are redefining experimental design and clinical translation. Explore actionable workflows, troubleshooting, and protocol refinements for robust results.

• Imipenem: Applied Workflows in Antibacterial and Sepsis Rese

  2026-04-27

  Imipenem, a semisynthetic thienamycin antibiotic, empowers advanced antibacterial research by combining broad-spectrum potency with immune modulation capabilities. Explore how APExBIO’s Imipenem elevates resistance modeling, immune assays, and animal sepsis studies through precise protocol design and troubleshooting insights.

• Nuclear Export Inhibition in TNBC: KPT-330 Combination Thera

  2026-04-27

  This study systematically identified and validated nuclear export inhibitor-based combination therapies in preclinical models of basal-like triple-negative breast cancer (TNBC). The key finding is that KPT-330 (Selinexor), when combined with GSK2126458, demonstrated synergistic tumor suppression in multiple TNBC models, highlighting a promising targeted approach for this aggressive cancer subtype.

• Puromycin dihydrochloride: Protocols and Troubleshooting Gui

  2026-04-26

  Puromycin dihydrochloride is an aminonucleoside antibiotic used to inhibit protein synthesis and select for cells expressing the pac gene. Researchers rely on it to establish and maintain stable cell lines, as well as to study translation and ribosome function. It is not suitable for experiments requiring intact protein synthesis or for cell types with unknown sensitivity.

• Anisomycin as a JNK Agonist: Applied Workflows & Troubleshoo

  2026-04-25

  Anisomycin stands out as a potent and specific JNK agonist, enabling targeted apoptosis and advanced cell signaling research. This article provides actionable workflows, protocol insights, and troubleshooting strategies for maximizing the impact of APExBIO's Anisomycin in cancer and neurobiology studies.

• Tubastatin A: HDAC6 Inhibitor for Targeted Cell Death Modula

  2026-04-24

  Tubastatin A stands out as a highly selective HDAC6 inhibitor, offering robust control of cell death pathways in inflammation, cancer biology, and myocardial protection. This guide delivers practical workflows, troubleshooting strategies, and new insights from recent in vivo cardiac models—empowering researchers to optimize their experimental designs.

• A Tunable Human Intestinal Organoid System: Balancing Renewa

  2026-04-24

  This study introduces a human intestinal organoid system that achieves a controlled and reversible balance between stem cell self-renewal and differentiation by using small molecule pathway modulators. The innovation enables high proliferative capacity and increased cellular diversity under a single culture condition, advancing the utility of organoids for disease modeling and high-throughput applications.

• Forsythoside E as a PKM2 Inhibitor: Workflows & Optimization

  2026-04-23

  Forsythoside E empowers immunometabolic research by enabling precise PKM2 inhibition and macrophage polarization workflows, with robust applications in sepsis-induced liver injury models. This guide translates cutting-edge mechanistic insight into reproducible experimental strategies and troubleshooting solutions for bench scientists.

• PKM2 Inhibitor (Compound 3k): Precision Targeting of Cancer

  2026-04-23

  Explore how PKM2 inhibitor (compound 3k) advances cancer research and immunometabolic modulation. This article uniquely analyzes its dual role as a pyruvate kinase M2 inhibitor in tumor and inflammatory models, grounded in the latest mechanistic discoveries.

• SB 203580 (SKU A8254): Reliable p38 MAPK Inhibition in Cell

  2026-04-22

  This article delivers scenario-driven, evidence-based guidance for using SB 203580 (SKU A8254) in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed studies and practical lab considerations, it demonstrates how this selective p38 MAPK inhibitor from APExBIO ensures experimental reproducibility and sensitivity across diverse research workflows.

15594 records 1/1040 page Next 12345 下5页 Last page